Login
Companies $NVAX
$8.07 +$0.01 (0.12%) After hours
NOVAVAX INC logo

NOVAVAX INC

novavax.com

What Do They Do?

Sells coronavirus vaccines to governments and commercial buyers, and supplies Matrix-M, a vaccine ingredient, to pharmaceutical partners.

How Do They Make Money?

Governments and commercial buyers pay for COVID-19 vaccine doses, while partners pay for adjuvant and other materials when units are delivered. License fees are paid when rights are granted; milestones when achieved; royalties as licensed products sell, and service payments over time.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product sales
Sold outright

61%
FY2022: 78%
Licensing, royalties, and other
Mix

39%
FY2022: 2.2%
Grants
0.0%
FY2022: 19%

Who Are Their Customers?

Governments buy vaccine doses under supply agreements. U.S. commercial doses move mainly through pharmaceutical wholesalers to retailers and health care providers; pharmaceutical partners buy adjuvant and other materials and license vaccine technology.

Do Revenues Turn Into Profits?

Yes. It kept 39 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$250.2M.

Operating income, FY2025
40% of revenue
▲ Turned profitable vs FY2024 (−$248.9M, −36%)
Net income, FY2025
39% of revenue
▲ Turned profitable vs FY2024 (−$187.5M, −27%)
Free cash flow, FY2025
−22% of revenue
▼ −149% (Loss) vs FY2024 (−$100.3M, −15%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −3%
vs $70.4M in Q3 FY2025
Net income
▲ +84% (Loss)
vs −$202.4M in Q3 FY2025
Product sales share of revenue vs 19.1% in Q3 FY2025

Flat. Revenue was $1.1B in FY2025, about the same as the $1.1B of FY2021.

Vaccine commercialization shifts to partners The earlier report describes Novavax as discovering, developing and commercializing vaccines; the latest says Sanofi leads Nuvaxovid commercialization while Novavax focuses on partnerships.

Matrix-M licensing expands The earlier report emphasizes supplying Matrix-M for partner vaccines; the latest adds non-exclusive licenses allowing Sanofi and Pfizer to use the adjuvant in vaccine programs.

Pipeline broadens beyond infectious diseases The earlier report centers on respiratory and emerging infectious diseases; the latest also describes exploring opportunities beyond infectious diseases.

Revenue over time
Product sales Licensing, royalties, and other Grants Royalties and other
$2B$1B$0

Who Do They Compete With?

Competes with Pfizer, Moderna, Sanofi, GSK, and Seqirus

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support